참고문헌 급성 단순 신우신염

1. Karlowsky JA, Hoban DJ, Decorby MR, Laing NM, Zhanel GG. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother 2006;50:2251-4.

2. Zhanel GG, Hisanaga TL, Laing NM, DeCorby MR, Nichol KA, Weshnoweski B, et al. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 2006;27:468-75.

3. Wie SH, Chang UI, Kim HW, Kim YS, Kim SY, Hur j, et al. Clinical features and antimicrobial resistance among clinical isolates of women with community-acquired acute pyelonephritis in 2001-2006. Infect Chemother 2007;39:9-16.

4. Ki M, Park T, Choi B, Foxman B. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. American Journal of Epidemiology 2004;160:985-93.

5. Lee DG, Jeon SH, Lee CH, Lee SJ, Kim JI, Chang SG. Acute pyelonephritis: clinical characteristics and the role of the surgical treatment. J Korean Med Sci 2009;24:296-301.

6. Lee DS, Choe HS, Lee SJ, Bae WJ, Cho HJ, Yoon BI, et al. Antimicrobial susceptibility pattern and epidemiology of female urinary tract infections in South Korea, 2010-2011. Antimicrob Agents Chemother 2013;57:5384-93.

7. Scholes D, Hooton TM, Roberts PL, Gupta K, Stapleton AE, Stamm WE. Risk factors associated with acute pyelonephritis in healthy women. Ann Intern Med 2005;142:20-7.

8. Busch R, Huland H. Correlation of symptoms and results of direct bacterial localization in patients with urinary tract infections. J Urol 1984;132:282-5.

9. King C, Garcia Alvarez L, Holmes A, Moore L, Galletly T, Aylin P. Risk factors for healthcareassociated urinary tract infection and their applications in surveillance using hospital administrative data: a systematic review. J Hosp Infect 2012;82:219-26.

10. Jung YH, Cho IR, Lee SE, Lee KE, Kim JG, Jeon JS, et al. Comparative analysis of clinical parameters in acute pyelonephritis. Korean J Urol 2007;48:29-34.

11. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents 2008;31 Suppl 1:S15-8.

12. Hwang BY, Lee JG, Park DW, Lee YJ, Kim SB, Eom JS, et al. Antimicrobial susceptibility of causative microorganisms in adults with acute pyelonephritis at one university-affiliated hospital in southwestern Seoul. Infect Chemother 2003;2003:277-82.

13. Wie S, Choi S, Lee D, Kim S, Kim S, Yoo J, et al. Antibiotic Sensitivity of the Causative Organisms and Use of Antibiotics in Women with Community-Acquired Acute Pyelonephritis. Korean J Infect Dis 2002;34:353-9.

14. Park JH, Wee JH, Choi SP, Park KN. Serum procalcitonin level for the prediction of severity in women with acute pyelonephritis in the ED: value of procalcitonin in acute pyelonephritis. Am J Emerg Med 2013;31:1092-7.

15. Ha YE, Kang CI, Wi YM, Chung DR, Kang ES, Lee NY, et al. Diagnostic usefulness of procalcitonin as a marker of bacteremia in patients with acute pyelonephritis. Scand J Clin Lab Invest 2013;73:444-8.

16. Velasco M, Martinez JA, Moreno-Martinez A, Horcajada JP, Ruiz J, Barranco M, et al. Blood cultures for women with uncomplicated acute pyelonephritis: are they necessary? Clin Infect Dis 2003;37:1127-30.

17. Mitterberger M, Pinggera GM, Colleselli D, Bartsch G, Strasser H, Steppan I, et al. Acute pyelonephritis: comparison of diagnosis with computed tomography and contrast-enhanced ultrasonography. BJU Int 2008;101:341-4.

18. Browne RF, Zwirewich C, Torreggiani WC. Imaging of urinary tract infection in the adult. Eur Radiol 2004;14 Suppl 3:E168-83.

19. Paick SH, Choo GY, Baek M, Bae SR, Kim HG, Lho YS, et al. Clinical value of acute pyelonephritis grade based on computed tomography in predicting severity and course of acute pyelonephritis. J Comput Assist Tomogr 2013;37:440-2.

20. Ha SK, Seo JK, Kim SJ, Park SH, Park CH, Lee HY, et al. Acute pyelonephritis focusing on perfusion defects on contrast enhanced computerized tomography(CT) scans and its clinical outcome. Korean J Intern Med 1997;12:122-7.

21. Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol 2008;54:1164-75.

22. Talan DA, Stamm WE, Hooton TM, Moran GJ, Burke T, Iravani A, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial. JAMA 2000;283:1583-90.

23. Klausner HA, Brown P, Peterson J, Kaul S, Khashab M, Fisher AC, et al. A trial of levofloxacin 750mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis. Curr Med Res Opin 2007;23:2637-45.

24. Peterson J, Kaul S, Khashab M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 2008;71:17-22.

25. Cronberg S, Banke S, Bergman B, Boman H, Eilard T, Elbel E, et al. Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime. Scand J Infect Dis 2001;33:339-43.

26. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician 2011;84:771-6.

27. Stamm WE, McKevitt M, Counts GW. Acute renal infection in women: treatment with trimethoprim-sulfamethoxazole or ampicillin for two or six weeks. A randomized trial. Ann Intern Med 1987;106:341-5.

28. Richard GA, Klimberg IN, Fowler CL, Callery-D'Amico S, Kim SS. Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 1998;52:51-5.

29. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15 Suppl 1:S216-27.

30. Wells WG, Woods GL, Jiang Q, Gesser RM. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy. J Antimicrob Chemother 2004;53 Suppl 2:ii67-74.

31. Mouton YJ, Beuscart C. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group. J Antimicrob Chemother 1995;36 Suppl A:145-56.

32. Giamarellou H. Low-dosage cefepime as treatment for serious bacterial infections. J Antimicrob Chemother 1993;32 Suppl B:123-32.

33. Naber KG, Savov O, Salmen HC. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int J Antimicrob Agents 2002;19:95-103.

34. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009;53:3782-92.